High Risk Smoldering Multiple Myeloma (HR-SMM)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which High Risk Smoldering Multiple Myeloma (HR-SMM) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

Not Yet RecruitingPhase 3

NCT07393282

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with…

Location not specified270 participantsStarted 2026-03-25

Treatment: Linvoseltamab, Daratumumab